Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-05-25, Stock:NVS, The news for the past five days is as follows:
2018-05-18: NEWS1: CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI.NEWS2: Cohen lawyers object to Stormy Daniels' attorney Michael Avenatti intervening in New York case.NEWS3: After hullabaloo, Greek lawmakers drop Novartis probe against ex ministers.NEWS4: Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst.NEWS5: Health Care Sector Update for 05/18/2018: AMRX,VLRX,AMGN,NVS,AZN.NEWS6: Health Care Sector Update for 05/18/2018: AMRX,VLRX,AMGN,NVS,AZN.NEWS7: FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs.NEWS8: Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug.NEWS9: Intraday Update: Small Caps Keep the Faith, Blue Chips Blue in the Face.NEWS10: Intraday Update: Small Caps Keep the Faith, Blue Chips Blue in the Face.NEWS11: Health Care Sector Update for 05/18/2018: VLRX,AMGN,NVS,AZN.NEWS12: Health Care Sector Update for 05/18/2018: VLRX,AMGN,NVS,AZN.NEWS13: Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up.NEWS14: Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up.NEWS15: Novartis AG -- Moody's: Aimovig approval credit positive for Amgen and Novartis.NEWS16: Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug.NEWS17: ‘Holy of holies’ — Inside the financial crime database that sprung a leak.NEWS18: Amgen&apos;s Migraine Drug Aimovig Gets FDA Approval, Shares Up.NEWS19: Label Expansion May Boost Cabometyx’s Revenue in 2018.NEWS20: Amgen Stock Rises over 2% on Drug Approvals.NEWS21: The Swiss Stock Market Fell On Broad Weakness.NEWS22: The Swiss Stock Market Fell On Broad Weakness.NEWS23: Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved.NEWS24: Cabometyx Is Expected to Witness a Robust Revenue Rise in 2018.NEWS25: Free Stock Performance Review on Teva Pharma and Three Other Healthcare Sector.NEWS26: Novartis, Amgen Get FDA Nod for Migraine Drug.NEWS27: The FDA Approved a Promising New Shot to Treat Migraines and Now the Drugmakers’ Stocks Are Rising.NEWS28: FDA approves anti-migraine drug from Novartis, Amgen.
2018-05-21: NEWS1: Roche (RHHBY) Announces Positive Data on Hemophilia Drug.NEWS2: Should The FDA Be Shaming Drug Companies? Financial Advisors' Daily Digest.NEWS3: Should The FDA Be Shaming Drug Companies? Financial Advisors' Daily Digest.NEWS4: Migraine Space in Focus as AMGN/NVS' Aimovig Gets FDA Nod.NEWS5: Migraine Space in Focus as AMGN/NVS' Aimovig Gets FDA Nod.NEWS6: Does Novartis AG’s (NYSE:NVS) Debt Level Pose A Problem?.NEWS7: Migraine Space in Focus as AMGN/NVS&apos; Aimovig Gets FDA Nod.
2018-05-22: NEWS1: Why Amgen&apos;s In Trouble — And Should Take Notes From Biogen, Celgene.NEWS2: Why Did JNJ Scrap Its Alzheimer’s Drug Mid-Stage Trial?.NEWS3: Wall Street Sees Upside of More than 17% for JNJ in the Next Year.NEWS4: The Swiss Stock Market Dipped After Long Holiday Weekend.NEWS5: The Swiss Stock Market Dipped After Long Holiday Weekend.NEWS6: [$$] Cohen Probe Trips Up Bridgewater Plan for Board.NEWS7: New Migraine Drugs Offer Hope to Sufferers.
2018-05-23: NEWS1: Should You Hold Momenta (MNTA) Stock in Your Portfolio?.NEWS2: Should You Hold Momenta (MNTA) Stock in Your Portfolio?.NEWS3: Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis.NEWS4: Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis.NEWS5: Why AveXis chose Durham for its 200-job expansion.NEWS6: Should You Expect Novartis AG (VTX:NOVN) To Continue Delivering An ROE Of 11.33%?.NEWS7: The Swiss Stock Market Pulled Back On Broad Weakness.NEWS8: The Swiss Stock Market Pulled Back On Broad Weakness.
2018-05-24: NEWS1: Is Genome Editing the Next Biotech Breakthrough?.NEWS2: Is Genome Editing the Next Biotech Breakthrough?.NEWS3: FDA Confirms September Action Date for Teva's Migraine Drug.NEWS4: FDA Confirms September Action Date for Teva's Migraine Drug.NEWS5: Novartis Gets Approval for Remicade Biosimilar in Europe.NEWS6: Novartis Gets Approval for Remicade Biosimilar in Europe.NEWS7: FDA Confirms September Action Date for Teva&apos;s Migraine Drug.NEWS8: bluebird's Lenti-D Gets Breakthrough Therapy Status From FDA.NEWS9: bluebird's Lenti-D Gets Breakthrough Therapy Status From FDA.NEWS10: Noteworthy ETF Inflows: VXUS, NSRGY, NVS, RY.NEWS11: Noteworthy ETF Inflows: VXUS, NSRGY, NVS, RY.NEWS12: Is This Little Biotech the Best Migraine Stock to Buy Now?.NEWS13: Is This Little Biotech the Best Migraine Stock to Buy Now?.NEWS14: Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for May 25, 2018.NEWS15: Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for May 25, 2018.NEWS16: Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings.NEWS17: The Swiss Stock Market Finished Lower After Early Gains Erode.NEWS18: The Swiss Stock Market Finished Lower After Early Gains Erode.

Answer: Decrease